Active B&O suppository of belladonna — Competitive Intelligence Brief

Active B&O suppository of belladonna (Active B&O suppository of belladonna) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Gastroenterology.

marketed Anticholinergic agent Muscarinic acetylcholine receptors (M1-M5) Gastroenterology Small molecule

Target snapshot

Active B&O suppository of belladonna (Active B&O suppository of belladonna) — Edgar LeClaire, MD. Belladonna alkaloids block muscarinic acetylcholine receptors to reduce smooth muscle contractions and secretions in the gastrointestinal and urinary tracts.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Active B&O suppository of belladonna TARGET	Active B&O suppository of belladonna	Edgar LeClaire, MD	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1-M5)
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Oxybutynin ER	Oxybutynin ER	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)
Atropine Sulfate 1% Oph Soln	Atropine Sulfate 1% Oph Soln	State University of New York College of Optometry	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1, M3)
Topical cyclopentolate and phenylephrine	Topical cyclopentolate and phenylephrine	Dar El Oyoun Hospital	marketed	Anticholinergic agent + alpha-1 adrenergic agonist	Muscarinic acetylcholine receptor (cyclopentolate); alpha-1 adrenergic receptor (phenylephrine)
scopolamine transdermal	scopolamine transdermal	Stony Brook University	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1, M3, M5)
Transdermal Scopolamine	Transdermal Scopolamine	Repurposed Therapeutics, Inc.	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class